Literature DB >> 2473699

Acute splenic sequestration crises in Saudi children with sickle cell disease.

M M Salamah1, A A Mallouh, J A Hamdan.   

Abstract

Sickle cell disease (SCD) is a common disease in the Eastern Province of Saudi Arabia. Twenty per cent of the population have sickle cell trait and 1.75% have SCD. In the first 2 years of life, infection, hand-foot syndrome and acute splenic sequestration crisis (ASSC) are the most common complications of this disease. The classical characteristics of an ASSC, the subject of this paper, are sudden and rapid enlargement of the spleen, secondary to the massive pooling of red blood cells in the splenic sinusoids in a functioning spleen. Less common minor attacks of ASSC have been described recently. An ASSC is one of the most common causes of death in infants with SCD. The underlying cause and the precipitants of attacks of ASSC remain unknown. Seventeen children with ASSC were seen. Clinically, they had minor ASSC; three developed hypersplenism and four underwent splenectomy for recurrent attacks of ASSC. None of these 17 children had the classical ASSC described in black children where peripheral circulatory shock is encountered.

Entities:  

Mesh:

Year:  1989        PMID: 2473699     DOI: 10.1080/02724936.1989.11748610

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN: 0272-4936


  3 in total

1.  Splenic syndrome in patients at high altitude with unrecognized sickle cell trait: splenectomy is often unnecessary.

Authors:  Anwar Sheikha
Journal:  Can J Surg       Date:  2005-10       Impact factor: 2.089

2.  Laparoscopic cholecystectomy in 427 adults with sickle cell disease: a single-center experience.

Authors:  Abdulrahman S Al-Mulhim; Abdulmohsen A Al-Mulhim
Journal:  Surg Endosc       Date:  2009-05-15       Impact factor: 4.584

3.  Physiologic effects of pneumoperitoneum in adults with sickle cell disease undergoing laparoscopic cholecystectomy (a case control study).

Authors:  Mohamed A M Youssef; Abdulrahman Al Mulhim
Journal:  Surg Endosc       Date:  2007-11-20       Impact factor: 4.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.